A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Exclusion Criteria

• •Participant has a history of active skin disease other than HS that could interfere with the assessment of HS.
• •Participant has active tuberculosis (TB) or concurrent treatment for latent TB or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.
• •Participant has prior exposure to anti-interleukin-1 (anti-IL-1) treatment within 3 months or 5 half-lives, whichever is longer, prior to baseline.
• •Participant has received prescription topical therapies (including topical antibiotics) within 14 days prior to the Baseline visit.
• •Participant has received systemic non-biologic therapies that can also be used to treat HS within 4 weeks prior to the Baseline visit.
• •Participant has received any systemic (including oral) antibiotic treatment within 4 weeks prior to the Baseline visit.